333954-83-9

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(4-chlorophenoxy)-, 1,1-dimethylethyl ester
• Synonyms: 4-(4-chloro-phenoxy)-piperidin-1-carboxylic acid tert-butyl ester;tert-butyl 4-(4-chlorophenoxy)-1-piperidinecarboxylate;4-(4-chlorophenoxy)-piperidine-1-carboxylic acid tert-butyl ester;4-(4-chlorophenoxy)piperidine-1-carboxylic acid tert-butyl ester;4-(4-chloro-phenoxy)-piperidinecarboxylic acid t-butyl ester
• CAS NO: 333954-83-9
• Molecular Formula: C16H22ClNO3
• Molecular Weight: 311.809
• Mol File: 333954-83-9.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(4-chlorophenoxy)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(4-chlorophenoxy)-, 1,1-dimethylethyl ester(333954-83-9)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(4-chlorophenoxy)-, 1,1-dimethylethyl ester(333954-83-9)

Safety Data

• Hazardous Substances Data: 333954-83-9(Hazardous Substances Data)

Usage

Chemical category

Non-steroidal anti-inflammatory drug (NSAID)

Use

Relief of pain and inflammation associated with osteoarthritis in dogs

Mechanism of action

Inhibition of prostaglandin production

Administration

Oral tablet

Metabolism

In the liver

Value in veterinary medicine

Management of chronic pain associated with osteoarthritis in dogs

Upstream product

• 352-33-0 1-Chloro-4-fluorobenzene 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 106-48-9 4-chloro-phenol 

Downstream Products

• 63843-53-8 4-(4-chlorophenoxy)piperidine hydrochloride 
• 442198-94-9 5-Chloro-N-[(1S)-2-({2-[4-(4-chlorophenoxy)-1-piperidinyl]-2-oxoethyl}amino)-2-oxo-1-(2-pyridylmethyl)ethyl]-1-benzofuran-2-carboxamide 
• 442198-93-8 (2E)-3-(4-Chlorophenyl)-N-[(1S)-2-({2-[4-(4-chlorophenoxy)-1-piperidinyl]-2-oxoethyl}amino)-2-oxo-1-(2-pyridylmethyl)ethyl]-2-propenamide 
• 97839-99-1 4-(4-chlorophenoxy)-piperidine 

Relevant articles and documents

MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS

The invention provides compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof (I) wherein ring A represents group A-I or A- II (A-I, A-II) A1, A2, A3, A4 represent independently C(R4aa) or N, wherein no more than one of A1, A2, A3, and A4 represents N; A5 represents C(R4b) or N; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a and R4aa and R4b are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.

NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS

The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS

The new kynurenic acid amide derivatives of formula (I): and optical antipodes, racemates and the salts thereof are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of